The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
Open accessAbstract
Treatment with immune checkpoint inhibitors (ICPIs) extends survival in a proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number of somatic mutations per DNA megabase (Mb)—has emerged as a proxy for neoantigen burden that is an independent biomarker associated with ICPI outcomes. Based on findings from recent studies, TMB can be reliably estimated using validated algorithms from next-generation sequencing assays that interrogate a sufficiently large subset of the exome as an alternative to whole-exome sequencing. Biological processes contributing to elevated TMB can result from exposure to cigarette smoke and ultraviolet radiation, from deleterious mutations in mismatch repair leading to microsatellite instability, or from mutations in the DNA repair machinery. A variety of clinical studies have shown that patients with higher TMB experience longer survival and greater response rates following treatment with ICPIs compared with those who have lower TMB levels; this includes a prospective randomized clinical trial that found a TMB threshold of ≥10 mutations per Mb to be predictive of longer progression-free survival in patients with non-small cell lung cancer. Multiple trials are underway to validate the predictive values of TMB across cancer types and in patients treated with other immunotherapies. Here we review the rationale, algorithm development methodology, and existing clinical data supporting the use of TMB as a predictive biomarker for treatment with ICPIs. We discuss emerging roles for TMB and its potential future value for stratifying patients according to their likelihood of ICPI treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 17×
“Greally et al. (2018) [65] Retrospective study of tumor tissue samples Esophagogastric cancer n = 120 Various immune checkpoint inhibitors CGP ≥7.4 mutations per Mb High TMB vs. low TMB, OS: 27.1 months vs. 8.4 months (p = .063) Goodman et al. (2017) [11] Retrospective study of clinical records Locally advanced or met…”
BackgroundInfluentialMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 1×
“…85% vs. 29% vs. 14% (p < .001) • Median PFS: not reached vs. 89 days vs. 86 days (p < .001) • Median OS: not reached vs. 300 days vs. 375 days (p < .001) Rizvi et al. (2015) [10] Prospective study NSCLC Discovery cohort: n = 16; validation cohort: n = 18 Pembrolizumab CGP >median mutations per…”
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“The evidence of ICPI efficacy in MSI-high disease led to the first tumor-agnostic FDA approval for pembrolizumab for MSIhigh or MMR-deficient tumors independent of anatomic origin [27, 28, 70].”
BackgroundPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“IMvigor210 [46, 64] Single-arm, phase II trial Advanced UC n = 310 1st-line atezolizumab CGP ≥16 mutations per Mb There was a greater proportion of TMB patients with ≥16 mutations/Mb among responders vs.”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 3×
“(2014) [22] Retrospective study of tumor tissue samples Malignant melanoma Discovery cohort: n = 25; validation cohort: n = 39 Ipilimumab or tremelimumab WES NA Higher TMB in long-term benefit subgroup vs.”
BackgroundResultTumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · cited 4×
“1 mutations/Mb for atezolizumab in NSCLC; Tables 1, 2) [45, 46, 61, 66].”
BackgroundInfluentialRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationAnalysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Self-citationZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · cited 1×
“Goodman and colleagues [11] suggested a pantumor cutoff of 20 mutations per Mb, and Yarchoan and colleagues [103] have reported a nearly linear relationship between TMB and ORR.”
BackgroundGenomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 4×
“therapy, this represents an area of future investigation [54, 61].”
BackgroundResultInfluentialAn immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · cited 1×
“…both cohorts: • PFS: HR, 0.19 (95% CI: 0.08–0.47; p = .0004) TMB > median vs. others, discovery cohort: • DCB: 73% vs. 13% (p = .04) • ORR: 63% vs. 0% (p = .03) Van Allen et al. (2015) [24] Retrospective study of tumor tissue samples Metastatic melanoma n = 110 Ipilimumab WES NA TMB was…”
InfluentialFehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Self-citationBalar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · cited 2×
“1 mutations/Mb for atezolizumab in NSCLC; Tables 1, 2) [45, 46, 61, 66].”
BackgroundFrampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“The two quality control metrics that should be considered when evaluating samples for TMB are median depth of sequencing coverage and coverage uniformity, as coverage is directly related to the sensitivity of calling both single nucleotide variants and indels, the two components that contribute to the TMB calculation…”
BackgroundNeoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 1×
“Additionally, KRAS mutations have been associated with improved treatment outcomes in NSCLC [30, 82, 84, 85], and certain classes of alterations in JAK1, MDM2/MDM4, ARID1A, and STK11 have predicted a lack of response to ICPIs in a high 20.”
BackgroundSelf-citationNeoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · cited 5×
“When properly designed and sufficient in size, these assays can assess tumor mutational burden (TMB; the number of somatic mutations per megabase [Mb] of sequenced DNA), which is a novel biomarker and a newly established independent predictor of ICPI treatment outcome [11, 12].”
BackgroundMethodInfluentialHirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G., Malboeuf, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0134-3 · Cited by 1,157
Self-citationMutational signatures associated with tobacco smoking in human cancer
Alexandrov, L. B., Ju, Y. S., Haase, K., Van Loo, P., Martincorena, I., Nik-Zainal, S., Totoki, Y., Fujimoto, A., Nakagawa, H., Shibata, T., et al. (2016) · Science · doi:10.1126/science.aag0299 · Cited by 1,100 · cited 1×
“Exposure to environmental carcinogens, such as cigarette smoke and ultraviolet radiation, has been shown to cause cancers with the highest number of somatic mutations [13, 40, 41].”
BackgroundHellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · cited 3×
“Although PD-L1 overexpression is associated with improved ICPI response and is common among patients with high TMB levels, several studies have concluded that TMB and PD-L1 expression are independent predictive biomarkers [12, 25, 26, 74].”
BackgroundHellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
Comprehensive Analysis of Hypermutation in Human Cancer
Campbell, B. B., Light, N., Fabrizio, D., Zatzman, M., Fuligni, F., de Borja, R., Davidson, S., Edwards, M., Elvin, J. A., Hodel, K. P., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.048 · Cited by 765
Self-citationNecchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Miao, D., Margolis, C. A., Vokes, N. I., Liu, D., Taylor-Weiner, A., Wankowicz, S. M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0200-2 · Cited by 620
Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z. D., Zou, J., Wang, C., Kapoor, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0012-z · Cited by 562
Merino, D. M., McShane, L. M., Fabrizio, D., Funari, V., Chen, S.-J., White, J. R., Wenz, P., Baden, J., Barrett, J. C., Chaudhary, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000147 · Cited by 507
Self-citationTargeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481 · cited 3×
“1 mutations/Mb for atezolizumab in NSCLC; Tables 1, 2) [45, 46, 61, 66].”
BackgroundInfluentialSelf-citationWang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7098 · Cited by 471 · cited 1×
“Additionally, TMB measurement from circulating tumor DNA, derived from blood specimens (bTMB), was recently shown to be predictive of survival in patients with NSCLC who were treated with atezolizumab, and several ongoing trials are evaluating the prospective efficacy of bTMB in a first-line NSCLC setting [56, 97, 98,…”
BackgroundBrahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30690-3 · Cited by 348
Snyder, A., Nathanson, T., Funt, S. A., Ahuja, A., Buros Novik, J., Hellmann, M. D., Chang, E., Aksoy, B. A., Al-Ahmadie, H., Yusko, E., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002309 · Cited by 341
High response rate to PD-1 blockade in desmoplastic melanomas
Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature · doi:10.1038/nature25187 · Cited by 338 · cited 1×
“(2018) [20] Retrospective review of pathology reports Advanced desmoplastic melanoma n = 60 PD-1 or PD-L1 blockade therapy WES NA Patients with desmoplastic melanoma had substantial clinical benefit from PD-1 or PD-L1 immune checkpoint blockade therapy likely resulting from high TMB, increased CD8 density, and high ex…”
BackgroundSomatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072182 · Cited by 334
Innocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01798 · Cited by 317 · cited 1×
“TMB >8 in the phase III SWOG 80405 trial [108].”
BackgroundFabrizio, D. A., George Jr, T. J., Dunne, R. F., Frampton, G., Sun, J., Gowen, K., Kennedy, M., Greenbowe, J., Schrock, A. B., Hezel, A. F., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.06 · Cited by 260
Self-citationTeng, F., Meng, X., Kong, L., & Yu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.014 · Cited by 243
Stenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 239
Campesato, L. F., Barroso-Sousa, R., Jimenez, L., Correa, B. R., Sabbaga, J., Hoff, P. M., Reis, L. F. L., Galante, P. A. F., & Camargo, A. A. (2015) · Oncotarget · doi:10.18632/oncotarget.5950 · Cited by 226
Gong, J., Wang, C., Lee, P. P., Chu, P., & Fakih, M. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0016 · Cited by 207
Spigel, D. R., Schrock, A. B., Fabrizio, D., Frampton, G. M., Sun, J., He, J., Gowen, K., Johnson, M. L., Bauer, T. M., Kalemkerian, G. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9017 · Cited by 177
Self-citationSize matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
Buchhalter, I., Rempel, E., Endris, V., Allgäuer, M., Neumann, O., Volckmar, A., Kirchner, M., Leichsenring, J., Lier, A., von Winterfeld, M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31878 · Cited by 172
Owada-Ozaki, Y., Muto, S., Takagi, H., Inoue, T., Watanabe, Y., Fukuhara, M., Yamaura, T., Okabe, N., Matsumura, Y., Hasegawa, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.003 · Cited by 170
Biomarker validation and testing
Hayes, D. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.004 · Cited by 167
The expanding role of immunotherapy
Martín-Liberal, J., de Olza, M. O., Hierro, C., Gros, A., Rodon, J. A., & Tabernero, J. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.008 · Cited by 142
The role of neoantigen in immune checkpoint blockade therapy
Yi, M., Qin, S., Zhao, W., Yu, S., Chu, Q., & Wu, K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0120-y · Cited by 142
Albacker, L. A., Wu, J., Smith, P. G., Warmuth, M., Stephens, P. J., Zhu, P., Yu, L., & Chmielecki, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176181 · Cited by 140
Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A. P., Mohindra, N. A., Villaflor, V. M., & Giles, F. J. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.09.008 · Cited by 138
Chae, Y. K., Davis, A. A., Agte, S., Pan, A. P., Simon, N. I., Iams, W. T., Cruz, M. R. D. S., Tamragouri, K., Rhee, K., Mohindra, N. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0433 · Cited by 133
Gargiulo, P., Pepa, C. D., Berardi, S., Califano, D., Scala, S., Buonaguro, L., Ciliberto, G., Brauchli, P., & Pignata, S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.008 · Cited by 130
Endris, V., Buchhalter, I., Allgäuer, M., Rempel, E., Lier, A., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., Neumann, O., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32002 · Cited by 128
The Damaging Effect of Passenger Mutations on Cancer Progression
McFarland, C. D., Yaglom, J. A., Wojtkowiak, J. W., Scott, J. G., Morse, D. L., Sherman, M. Y., & Mirny, L. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3283-t · Cited by 126
Kim, J. H., Kim, H. S., & Kim, B. J. (2017) · Oncotarget · doi:10.18632/oncotarget.17594 · Cited by 125
Vaughn, D. J., Joaquim Bellmunt, B., Fradet, Y., Lee, J., Fong, L. H., Vogelzang, N. J., Climent, M. Á., Petrylak, D. P., Choueiri, T. K., Necchi, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9562 · Cited by 122
Peters, S., Creelan, B., Hellmann, M. D., Socinski, M. A., Reck, M., Bhagavatheeswaran, P., Chang, H., Geese, W. J., Paz-Ares, L. G., & Carbone, D. P. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct082 · Cited by 92
Kowanetz, M., Zou, W., Shames, D. S., Cummings, C. A., Rizvi, N. A., Spira, A. I., Frampton, G. M., Lévêque, V., Flynn, S., Mocci, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.343 · Cited by 86
Self-citationRozenblum, A. B., Ilouze, M., Dudnik, E., Dvir, A., Soussan‐Gutman, L., Geva, S., & Peled, N. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.021 · Cited by 84
Ramalingam, S. S., Hellmann, M. D., Awad, M. M., Borghaei, H., Gainor, J. F., Brahmer, J. R., Spigel, D. R., Reck, M., O'Byrne, K. J., Paz-Ares, L. G., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct078 · Cited by 71
Chae, Y. K., Anker, J. F., Bais, P., Namburi, S., Giles, F. J., & Chuang, J. H. (2017) · Oncotarget · doi:10.18632/oncotarget.23742 · Cited by 67
Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
Legrand, F. A., Gandara, D. R., Mariathasan, S., Powles, T. B., He, X., Zhang, W., Jhunjhunwala, S., Nickles, D., Bourgon, R., Schleifman, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12000 · Cited by 58
Self-citationKowanetz, M., Zou, W., Shames, D. S., Cummings, C. A., Rizvi, N. A., Spira, A. I., Frampton, G. M., Lévêque, V., Flynn, S., Mocci, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw363.25 · Cited by 48
Self-citationPD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
Lin, Z., Chen, X., Li, Z., Luo, Y., Fang, Z., Xu, B., & Han, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160485 · Cited by 43
Wang, C., Yu, X., & Wang, W. (2016) · Medicine · doi:10.1097/md.0000000000005539 · Cited by 37
Davis, A. A., Chae, Y. K., Agte, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.7_suppl.24 · Cited by 30
Fabrizio, D. A., Malboeuf, C. M., Lieber, D. S., Zhong, S., He, J., White, E., Coyne, M. J., Silterra, J., Brennan, T., Ma, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx363.018 · Cited by 21
Self-citationHall, M. J., Gowen, K. A., Sanford, E. M., Elvin, J. A., Ali, S. M., Kaczmar, J. M., White, E. T., Malboeuf, C. M., Ross, J. S., Miller, V. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.1523 · Cited by 20
Self-citationPolymerase epsilon mutations and concomitant β2-microglobulin mutations in cancer
Voutsadakis, I. A. (2018) · Gene · doi:10.1016/j.gene.2018.01.030 · Cited by 18
Mok, T. S. K., Gadgeel, S. M., Kim, E. S., Velcheti, V., Hu, S., Riehl, T., Schleifman, E., Paul, S. M., Mocci, S., Shames, D. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx380.084 · Cited by 17
Szustakowski, J. D., Green, G. A., Geese, W. J., Zerba, K. E., & Chang, H. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5528 · Cited by 12
Fabrizio, D. A., Milbury, C. A., Yip, W., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy269.054 · Cited by 12
Self-citationFrampton, G. M., Fabrizio, D. A., Chalmers, Z. R., Sun, J., Miller, V. A., & Stephens, P. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw363.01 · Cited by 4
Self-citationRothschild, S. I., Alborelli, I., Leonards, K., Leuenberger, L. P., Prince, S. S., Mertz, K. D., Poechtrager, S., Zippelius, A., Laubli, H. P., Haegele, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e14266 · Cited by 1
Rothschild, S. I., Jermann, P. M., Savic, S., Mertz, K. D., Zippelius, A., Quagliata, L., & Bubendorf, L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15075 · Cited by 1
Cited by
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 471
Milbury, C. A., Creeden, J., Yip, W.-K., Smith, D. L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., Skoletsky, J., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264138 · Cited by 376
Self-citationUnderstanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334
“Overall, TMB has been shown to stratify patients receiving immunotherapies by response rate and survival.(166)”
BackgroundWang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Veluswamy, R., Mack, P. C., Houldsworth, J., Elkhouly, E., & Hirsch, F. R. (2021) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.02.002 · Cited by 96
Metadata
- Authors
- Klempner, S. J., Fabrizio, D., Bane, S., Reinhart, M., Peoples, T., Ali, S. M., Sokol, E. S., Frampton, G., Schrock, A. B., Anhorn, R., & Reddy, P.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-02
- Volume
- 25
- Issue
- 1
- Pages
- e147-e159
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2978209487
- Cited by
- 391
- References
- 90
- FWCI
- 15.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.